Celltrion Pharm Inc. Discloses Business Group Status: Stable Financials, Majority Stake at 54.99%
Annual business group status disclosure of Celltrion Pharm, a member of Celltrion group, reporting financial status and governance as of prior fiscal year (Dec 31, 2025)
Total assets 759.4B KRW, total liabilities 323.5B KRW, total equity 436.0B KRW, debt ratio 74.2%, indicating stable financial structure
Revenue 536.4B KRW, operating profit 56.1B KRW, net income 38.8B KRW, showing solid profitability
Major shareholder Celltrion holds 54.99% of common shares, related parties total 55.38%, treasury shares 0.32%, minority shareholders 44.62%, ownership stable
Key related-party transactions: sales of goods/services to Celltrion 122.8B KRW, R&D service revenue from Celltrion 30.1B KRW
Board consists of 3 inside directors (Seo Jung-jin, Seo Jin-seok, Yoo Young-ho), 5 outside directors, 1 auditor; newly established ESG committee improves governance
[AI Summary]This is a routine disclosure of Celltrion Pharm's status with stable financial indicators and unchanged majority stake, resulting in a neutral impact on stock price.
KOSDAQ Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]